NT-proBNP and exercise capacity in adult patients with congenital heart disease and a prosthetic valve: a multicentre PROSTAVA study
| Autor: | Gertjan T. Sieswerda, Monique R.M. Jongbloed, R C Schoonbeek, B.J. Bouma, Y. J. van Slooten, J.P. van Melle, Petronella G. Pieper, A.P.J. van Dijk, Hendrik G. Freling, Tjark Ebels, Martijn C. Post, Rolf M. F. Berger |
|---|---|
| Přispěvatelé: | Cardiovascular Centre (CVC), ACS - Amsterdam Cardiovascular Sciences, Cardiology |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Cardiac function curve
medicine.medical_specialty Heart disease medicine.drug_class Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Internal medicine Pulmonary Valve Replacement Natriuretic peptide Medicine 030212 general & internal medicine cardiovascular diseases Congenital heart disease Prosthetic valve business.industry Exercise capacity medicine.disease Pulmonary valve replacement NT-proBNP Heart failure Cardiology Biomarker (medicine) Original Article Cardiology and Cardiovascular Medicine business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Netherlands Heart Journal Netherlands Heart Journal, 24, 653-665 Netherlands Heart Journal, 24, 11, pp. 653-665 Netherlands Heart Journal, 24(11), 653-665. Bohn, Stafleu, Van Loghum Netherlands Heart Journal, 24(11), 653-665 Netherlands heart journal, 24(11), 653-665. Bohn Stafleu van Loghum |
| ISSN: | 1876-6250 1568-5888 |
| Popis: | Contains fulltext : 171019.pdf (Publisher’s version ) (Open Access) OBJECTIVES: N-terminal Btype natriuretic peptide (NT-proBNP) is an important biomarker for the detection of heart failure. Adults with congenital heart disease (ACHD) and a prosthetic heart valve are at risk for heart failure. This study aimed to determine the value of NT-proBNP in ACHD patients with a prosthetic valve and investigate its relationship with cardiac function and exercise capacity. METHODS: In this multi-centre cross-sectional observational study, data regarding medical history, echocardiography, exercise testing (VO2peak) and laboratory blood evaluation (including NT-proBNP) were collected in ACHD patients with a single prosthetic valve (either homografts, heterografts or mechanical valves). RESULTS: A total of 306 ACHD patients with pulmonary valve replacement (PVR, n = 139), aortic valve replacement (n = 141), mitral valve replacement (n = 21) or tricuspid valve replacement (n = 5) were investigated. The majority of patients (77 %) were in NYHA class I or II. Elevated NT-proBNP levels (cut-off >/=125 pg/ml) were found in 50 % of the patients, with the highest levels in patients with mitral valve replacements. In this study population, NT-proBNP levels were associated with gender (p = 0.029) and VO2max (p < 0.001). In PVR patients, NT-proBNP levels were associated with lower VO2peak, also after adjustment for age, gender and age at valve replacement in a multivariate model (p = 0.015). CONCLUSIONS: In patients with ACHD and a prosthetic valve, elevated NT-proBNP levels are frequently observed despite preserved NYHA class. In PVR patients, a higher NT-proBNP level was associated with a lower VO2peak. These results may be of importance in the ongoing discussion about the timing of valve replacement in patients with CHD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink